Company Intelligence
Generate Biomedicines
Generate Biomedicines provides enterprise-grade artificial intelligence solutions, delivering specialized Generate Biomedicines Platform technology designed to optimize mission-critical workflows across enterprise software developers and digital transformation teams.
- Headquarters
- Somerville, United States
- Website
- generatebiomedicines.com
- Founded
- 2018
- Status
- Active
- Products
- 1
- Reports
- 8
- Last reviewed
- Aug 2026
Overview
What this company is, what it builds, and who it serves.
Generate Biomedicines is a Healthcare AI company based in Somerville, United States, founded in 2018.
Somerville generative biology company programming protein therapeutics with AI from discovery through Phase 3 clinical programs.
Verified founder profiles on Brel: Geoffrey von Maltzahn PhD, Avak Kahvejian, Geoffrey von Maltzahn.
What it builds
Generate Biomedicines Platform
Why It Matters
Generate Biomedicines provides enterprise-grade artificial intelligence solutions, delivering specialized Generate Biomedicines Platform technology designed to optimize mission-critical workflows across enterprise software developers and digital transformation teams.
Products
Products and platforms connected to this company.
-
Generate Platform
Explore Generate Platform by Generate Biomedicines. Verified AI product intelligence covering core capabilities, Healthcare use cases, technical architecture...
View product intelligence
Founders
People linked to this company in the Brel founder graph.
Ecosystem
How this company connects across the Brel AI intelligence graph.
Company
Generate Biomedicines
Industry
Industries served
- Biotechnology
Products
Capabilities
Generate's AI learns from iterative design-build-test cycles at scale — each experimental result refining models that propose subsequent protein variants optimized for…
Features
- Generate Platform combining generative AI with large-scale biological experimentation to design protein therapeutics, inc
- including clinical-stage programs GB-0895 (anti-TSLP)
- partnered assets with Amgen
- Novartis
Integrations
- What the company does
- Generate Biomedicines integrates computational protein design with automated wet-lab testing to generate and optimize therapeutic candidates across modalities including antibodies, enzymes, and novel protein compositions.
Country
Use cases
Related companies
Official Resources
Official and developer links on file for this company.
Latest Developments
Verified developments and timeline notes on file.
Partnerships
- January 2024: Generate expanded Amgen collaboration and reported first patient dosed in GB-0895 Phase 1.
Frequently Asked Questions
What does Generate Biomedicines do?
Generate Biomedicines specializes in artificial intelligence, developing Generate Biomedicines Platform to support enterprise software developers and digital transformation teams with scalable, production-grade technology.
Where is Generate Biomedicines based and when was it founded?
Generate Biomedicines is based in United States and was founded in 2018.
What are the main products offered by Generate Biomedicines?
The flagship platform from Generate Biomedicines is Generate Biomedicines Platform, delivered primarily through b2b saas and enterprise api licensing.
Who are the primary target users of Generate Biomedicines?
Generate Biomedicines primarily serves enterprise software developers and digital transformation teams seeking reliable artificial intelligence implementations.
Sources & Verification
How this profile is verified and where the information comes from.
Primary sources
Request a correction if you represent this company or believe information is inaccurate.